These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29927772)

  • 41. Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study.
    Visser S; Huisbrink J; van 't Veer NE; van Toor JJ; van Boxem AJM; van Walree NC; Stricker BH; Aerts JGJV
    Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30139775
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer.
    Takemoto S; Nakamura Y; Fukuda M; Senju H; Gyotoku H; Taniguchi H; Shimada M; Ikeda T; Yamaguchi H; Nakatomi K; Hayashi N; Soda H; Mukae H
    Thorac Cancer; 2017 Nov; 8(6):577-581. PubMed ID: 28771961
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status.
    Schuette W; Behringer D; Stoehlmacher J; Kollmeier J; Schmager S; Fischer von Weikersthal L; Schumann C; Buchmann J
    Clin Lung Cancer; 2015 Nov; 16(6):447-56. PubMed ID: 26094080
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
    Tamiya M; Tamiya A; Kaneda H; Nakagawa K; Yoh K; Goto K; Okamoto H; Shimokawa T; Abe T; Tanaka H; Daga H; Takeda K; Hirashima T; Atagi S
    Med Oncol; 2016 Jan; 33(1):2. PubMed ID: 26603297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
    Soria JC; Tan DSW; Chiari R; Wu YL; Paz-Ares L; Wolf J; Geater SL; Orlov S; Cortinovis D; Yu CJ; Hochmair M; Cortot AB; Tsai CM; Moro-Sibilot D; Campelo RG; McCulloch T; Sen P; Dugan M; Pantano S; Branle F; Massacesi C; de Castro G
    Lancet; 2017 Mar; 389(10072):917-929. PubMed ID: 28126333
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Posterior reversible encephalopathy syndrome possibly induced by pemetrexed maintenance therapy for lung cancer: a case report and literature review.
    Smets GJ; Loyson T; Van Paesschen W; Demaerel P; Nackaerts K
    Acta Clin Belg; 2018 Oct; 73(5):382-388. PubMed ID: 29173113
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pemetrexed and cyclophosphamide combination therapy for the treatment of non-small cell lung cancer.
    Li D; He S
    Int J Clin Exp Pathol; 2015; 8(11):14693-700. PubMed ID: 26823793
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.
    Sun Y; Wu YL; Zhou CC; Zhang L; Zhang L; Liu XY; Yu SY; Jiang GL; Li K; Qin SK; Ma SL; Han L; Quinlivan M; Orlando M; Zhang XQ
    Lung Cancer; 2013 Feb; 79(2):143-50. PubMed ID: 23182660
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Skin toxicities compromise prolonged pemetrexed treatment.
    Eguia B; Ruppert AM; Fillon J; Lavolé A; Gounant V; Epaud C; Milleron B; Moguelet P; Wislez M; Frances C; Cadranel J
    J Thorac Oncol; 2011 Dec; 6(12):2083-9. PubMed ID: 21892100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer.
    Liu Z; Wei Z; Hu Y; Gao F; Hao L; Fang P; Sun S; Li J; Jiao S
    Med Oncol; 2015 Aug; 32(8):216. PubMed ID: 26168982
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
    Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pemetrexed-induced skin sclerosis.
    Merklen-Djafri C; Imbert E; Courouge-Dorcier D; Schott R; Méraud JP; Muller C; Tebacher M; Springinsfeld G; Cribier B; Lipsker D
    Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):452-3. PubMed ID: 22397832
    [No Abstract]   [Full Text] [Related]  

  • 53. Pemetrexed disodium for the treatment of NSCLC: an update.
    Hsu JY; Wakelee H
    Drugs Today (Barc); 2008 Sep; 44(9):669-78. PubMed ID: 19137122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
    Ellis PM; Leighl NB; Hirsh V; Reaume MN; Blais N; Wierzbicki R; Sadrolhefazi B; Gu Y; Liu D; Pilz K; Chu Q
    Clin Lung Cancer; 2015 Nov; 16(6):457-65. PubMed ID: 26100229
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer.
    Xu B; Liu P; Yin Y; Liu P; Shu Y
    Biomed Pharmacother; 2013 Oct; 67(8):763-9. PubMed ID: 23790249
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Lu S; Ye M; Ding L; Tan F; Fu J; Wu B
    Oncotarget; 2017 Feb; 8(6):9996-10006. PubMed ID: 28036283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report.
    Sakhri L; Pinsolle J; Moro-Sibilot D; Pluchart H
    J Med Case Rep; 2017 Sep; 11(1):262. PubMed ID: 28915906
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison.
    Qi WX; Tang LN; He AN; Shen Z; Lin F; Yao Y
    Curr Med Res Opin; 2012 Apr; 28(4):643-50. PubMed ID: 22414178
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lung cancer.
    Crinò L; Foglietta J; Hamzaj A
    J Thorac Oncol; 2007 May; 2(5 Suppl):S24-6. PubMed ID: 17457226
    [No Abstract]   [Full Text] [Related]  

  • 60. The role of pemetrexed combined with targeted agents for non-small cell lung cancer.
    Konopa K; Jassem J
    Curr Drug Targets; 2010 Jan; 11(1):2-11. PubMed ID: 19839932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.